NPHS1 and diabetes mellitus: Nephrin immunostaining showed that APX-115 or losartan treatment significantly reversed diabetes-induced inhibition of nephrin expression (Figure 2D and 2E), suggesting that APX-115 or losartan could reverse podocyte injury in diabetes.